Carcinoembryonic antigen (CEA)-based cancer vaccines: Recent patents and antitumor effects from experimental models to clinical trials

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 3, 2012, Pages 265-296

  Turriziani, Mario ^a   Fantini, Massimo ^a   Benvenuto, Monica ^a   Izzi, Valerio ^a   Masuelli, Laura ^b   Sacchetti, Pamela ^b   Modesti, Andrea ^a   Bei, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cancer; CEA; CTL; Immunotherapy; Tumor antigen; Vaccine

Indexed keywords

9 BENZYL 8 HYDROXY 2 (2 METHOXYETHOXY)ADENINE; ADENOVIRUS VECTOR; ANTIIDIOTYPIC ANTIBODY; BACTERIAL VECTOR; BACULOVIRUS VECTOR; CALRETICULIN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DNA VACCINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; PLACEBO; QS 21; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSACTIVATOR PROTEIN; UNINDEXED DRUG; VIRUS VECTOR;

ANTIBODY TITER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE ACTIVATION; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; DISEASE MODEL; DRUG DESIGN; DRUG POTENTIATION; DRUG TARGETING; ESCHERICHIA COLI; GALLBLADDER CANCER; GENE REARRANGEMENT; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; KIDNEY CARCINOMA; LISTERIA MONOCYTOGENES; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; SALMONELLA; SHIGELLA; STOMACH CANCER; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VATER PAPILLA CARCINOMA; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY, ACTIVE; MODELS, ANIMAL; NEOPLASMS; PATENTS AS TOPIC;

EID: 84867563910     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212801820020     Document Type: Review

References (212)

1. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5(5): 344-66.
2. Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detect Prev 1988; 12(1-6): 321-55.
3. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23(4): 338-51.
4. Garcia M, Seigner C, Bastid C, Choux R, Payan MJ, Reggio H. Carcinoembryonic antigen has a different molecular weight in normal colon and in cancer cells due to N-glycosylation differences. Cancer Res 1991; 51(20): 5679-86.
5. Ura Y, Ochi Y, Hamazu M, Ishida M, Nakajima K, Watanabe T. Studies on circulating antibody against carcinoembryonic antigen (CEA) and CEA-like antigen in cancer patients. Cancer Lett 1985; 25(3): 283-95.
6. Konstadoulakis MM, Syrigos KN, Albanopoulos C, Mayers G, Golematis B. The presence of anti-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies. J Clin Immunol 1994; 14(5): 310-3.
7. Albanopoulos K, Armakolas A, Konstadoulakis MM, Leandros E, Tsiompanou E, Katsaragakis S, et al. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am J Gastroenterol 2000; 95: 1056-61.
8. Haidopoulos D, Konstadoulakis MM, Antonakis PT, Alexiou DG, Manouras AM, Katsaragakis SM, et al. Circulating anti-CEA antibodies in the sera of patients with breast cancer. Eur J Surg Oncol 2000; 26(8): 742-6.
9. Ladd J, Lu H, Taylor AD, Goodell V, Disis ML, Jiang S. Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf B Biointerfaces 2009; 70(1): 1-6.
10. Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer 1991; 48(6): 900-7.
11. Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992; 52(24): 6917-25.
12. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002; 62(23): 6944-51.
13. Hance KW, Zeytin HE, Greiner JW. Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: Evaluation of CEA-based cancer vaccines. Mutat Res 2005; 576(1-2): 132-54.
14. Mocellin S, Pilati P, Nitti D. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem 2009; 16(36): 4779-96.
15. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol 2010; 2010 pii: 596432.
16. Palena C, Schlom J. Vaccines against human carcinomas: Strategies to improve antitumor immune responses. J Biomed Biotechnol 2010; 2010: 380697.
17. Bei R, Scardino A. TAA polyepitope DNA-based vaccines: A potential tool for cancer therapy. J Biomed Biotechnol 2010; 2010: 102758.
18. Conry RM, LoBuglio AF, Kantor J, Schlom J, Loechel F, Moore SE, et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994; 54(5): 1164-8.
19. Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL, et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1995; 2(1): 59-65.
20. Luo Y, O'Hagan D, Zhou H, Singh M, Ulmer J, Reisfeld RA, et al. Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine 2003; 21(17-18): 1938-47.
21. Lund LH, Andersson K, Zuber B, Karlsson A, Engström G, Hinkula J, et al. Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer Gene Ther 2003; 10(5): 365-76.
22. Johansson S, Engström G, Winberg G, Hinkula J, Wahren B. Responses of mice immunized with a DNA vaccine encoding carcinoembryonic antigen (CEA). Vaccine 2006; 24(21): 4572-5.
23. Johansson S, Ek M, Wahren B, Stout R, Liu M, Hallermalm K. Intracellular targeting of CEA results in Th1-type antibody responses following intradermal genetic vaccination by a needle-free jet injection device. Sci World J 2007; 7: 987-99.
24. Li D, Hua S, Fan Y, Xu S, Duan X, Liu L, et al. DNA vaccine expressing repeated carcinoembryonic antigen (CEA)(625-667) induces strong immunity in mice. Immunol Lett 2011; 135(1-2): 124-8.
25. Boyle, B.J., Kuo, C., Arterburn, M.C., Tang, Y.T., Liu, C., Drmanac, R.T. Methods and materials relating to carcinoembryonic antigen-like (CEA-Like) polypeptides and polynucleotides. US20060052591 (2006).
26. Parrington, M., Zhang, L., Rovinski, B., Gritz, L.R., Greenhalgh, P. Modified CEA nucleic acid and expression vectors. US20100285065 (2010).
27. Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Silletti S, Lode HN, et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cellmediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 2001; 67(8): 4560-5.
28. Niethammer AG, Primus FJ, Xiang R, Dolman CS, Ruehlmann JM, Ba Y, et al. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine 2001; 20(3-4): 421-9.
29. Gillies SD, Lan Y, Wesolowski JS, Qian X, Reisfeld RA, Holden S, et al. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol 1998; 160(12): 6195-203.
30. Xiang R, Silletti S, Lode HN, Dolman CS, Ruehlmann JM, Niethammer AG, et al. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin Cancer Res 2001; 7(3 Suppl): 856s-64s.
31. Xiang, R., Reisfeld, R.A. DNA vaccine encoding CEA and a CD40 ligand and methods of use thereof. US20050287123 (2005).
32. Zhou H, Luo Y, Mizutani M, Mizutani N, Becker JC, Primus FJ, et al. A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest 2004; 113(12): 1792-8.
33. Song K, Chang Y, Prud'homme GJ. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther 2000; 7(18): 1527-35.
34. Chakrabarti R, Chang Y, Song K, Prud'homme GJ. Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA). Vaccine 2004; 22(9-10): 1199-205.
35. Zhou ZF, Peretz Y, Chang Y, Miao DS, Li X, Prud'homme GJ. Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination. Cancer Gene Ther 2003; 10(6): 491-9.
36. Chakrabarti R, Zhou ZF, Chang Y, Prud'homme GJ. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity. Vaccine 2005; 23(37): 4553-64.
37. Lima J, Jenkins C, Guerrero A, Triozzi PL, Shaw DR, Strong TV. A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF). Vaccine 2005; 23(10): 1273-83.
38. Dharmapuri S, Aurisicchio L, Neuner P, Verdirame M, Ciliberto G, La Monica N. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer Gene Ther 2009; 16(5): 462-72.
39. Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA, Köhler H. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990; 145(8): 2758-65.
40. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon KA, Chatterjee SK. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res 1997; 57(4): 728-34.
41. Baral RN, Saha A, Chatterjee SK, Foon KA, Krieg AM, Weiner GJ, et al. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immunol Immunother 2003; 52(5): 317-27.
42. Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother 2006; 55(5): 515-27.
43. Chatterjee, M., Kohler, H., Chatterjee, S.K., Foon, K.A. Murine anti-idiotype antibody 3H1. US5977315 (1999).
44. Chatterjee, M., Kohler, H., Chatterjee, S.K., Foon, K.A. Murine monoclonal anti-idiotype antibody 3H1 sequences for human carcinoembryonic antigen. US7090842 (2006).
45. Chatterjee, M., Foon, K.A., Chatterjee, S.K. Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1. US7300651 (2007).
46. Chatterjee, M., Foon, K.A. Compositions and methods for treating tumors bearing HMFG and CEA antigens. US20030152575 (2003).
47. Losman MJ, Novick KE, Goldenberg DM, Monestier M. Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal antiidiotype antibody. Int J Cancer 1994; 56(4): 580-4.
48. Leung, S.-O., Losman, M.J., Hansen, H. Humanization of an anticarcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications. US20080069775 (2008).
49. Durrant LG, Parsons T, Moss R, Spendlove I, Carter G, Carr F. Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses. Int J Cancer 2001; 92(3): 414-20.
50. Carter, G., Carr, F.J. Anti-idiotype anti-CEA antibody molecules and its use as cancer vaccine. US20050222392 (2005).
51. Schwegler C, Dorn-Beineke A, Nittka S, Stocking C, Neumaier M. Monoclonal anti-idiotype antibody 6G6. C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice. Cancer Res 2005; 65(5): 1925-33.
52. Pignatari GC, Takeshita D, Parise CB, Soares FA, de Moraes JZ, Han SW. Carcinoembryonic antigen (CEA) mimicry by an antiidiotypic scFv isolated from anti-Id 6. C4 hybridoma. J Biotechnol 2007; 127(4): 615-25.
53. Apetoh L, Locher C, Ghiringhelli F, Kroemer G, Zitvogel L. Harnessing dendritic cells in cancer. Semin Immunol 2011; 23(1): 42-9.
54. +CTL response by dendritic cell vaccine. Cancer Res 2005; 65(11): 4947-54.
55. Bae MY, Cho NH, Seong SY. Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tatcarcinoembryonic antigen derived from Escherichia coli. Clin Exp Immunol 2009; 157(1): 128-38.
56. Kim, T.-G., Cho, H.-I., An, C.-H., Kang, W.-K., Oh, S.-T. Nucleotide sequence encoding PTD and CEA fusion protein, TAT-CEA fusion protein, anti-tumor vaccine and pharmaceutical composition for treating tumor comprising the fusion protein. US7364743 (2008).
57. Kim S-G, Park M-Y, Kim C-H, Sohn H-J, Kim H-S, Park J-S, et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Vaccine 2008; 26(50): 6433-40.
58. Rubiolo, C. Dendritic cells. EP2450052 (2012).
59. Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res 2003; 63(11): 2844-54.
60. Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, et al. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res 2004; 64(14): 4995-5003.
61. Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res 2007; 67(6): 2881-92.
62. Saha A, Bhattacharya-Chatterjee M, Foon KA, Celis E, Chatterjee SK. Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. Int J Cancer 2009; 124(4): 877-88.
63. Saha A, Chatterjee SK. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand J Immunol 2010; 71(2): 70-82.
64. Oh S-T, Kim C-H, Park M-Y, Won E-H, Sohn H-J, Cho H-I, et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006; 24(15): 2860-8.
65. Kim, T.-G., Cho, H.-I., Kim, H.-J., Oh, S.-T. Dendrite cells transduced with recombinant adenovirus AdVCEA which generate CEA-specific cytotoxic T lymphocytes, vaccine and pharmaceutical composition comprising the same. US8012468 (2011).
66. Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, et al. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer 2007; 120(3): 585-93.
67. Kim H-S, Kim C-H, Park M-Y, Park J-S, Park H-M, Sohn H-J, et al. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model. Immunol Lett 2010; 131(1): 73-80.
68. Kim H-S, Park H-M, Park J-S, Sohn H-J, Kim S-G, Kim H-J, et al. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Vaccine 2010; 28(49): 7787-96.
69. Pereboev, A., Tsuladze, G., Bogdashin, I., Beistegui, I.E., Sagastibelza, J.J.L., Valtueña, J.M.P., Ugarriza, P.S. Adapter molecule for the delivery of adenovirus vectors. US20110076304 (2011).
70. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999; 59(3): 676-83.
71. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res 1995; 55(16): 3598-603.
72. Schlom, J., Kantor, J., Hodge, J.W. Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule. US6045802 (2000).
73. Schlom, J., Kantor, J., Hodge, J.W. Method of enhancing a targeted immune response against tumors. US7368116 (2008).
74. McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996; 56(10): 2361-7.
75. Schlom, J., Kantor, J.A. Recombinant virus expressing human carcinoembryonic antigen and methods of use thereof. US5698530 (1997).
76. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002; 62(20): 5770-7.
77. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001; 61(11): 4497-505.
78. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002; 62(23): 6944-51.
79. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003; 9(5): 1837-49.
80. Kudo-Saito C, Garnett CT, Wansley EK, Schlom J, Hodge JW. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity. Cancer Immunol Immunother 2007; 56(12): 1897-910.
81. Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 2006; 24(23): 4975-86
82. Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J, et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and longterm survival in CEA. Tg/MIN mice. Cancer Res 2004; 64(10): 3668-78.
83. Chakraborty M, Schlom J, Hodge JW. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated Tcell responses. Cancer Immunol Immunother 2007; 56(9): 1471-84.
84. Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, et al. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol Immunother 2008; 57(8):1173-83.
85. Farsaci B, Sabzevari H, Higgins JP, Di Bari MG, Takai S, Schlom J, et al. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer 2010; 127(7): 1603-13.
86. Hance KW, Rogers CJ, Zaharoff DA, Canter D, Schlom J, Greiner JW. The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines. Clin Cancer Res 2009; 15(7): 2387-96.
87. Hodge JW, Poole DJ, Aarts WM, Gómez Yafal A, Gritz L, Schlom J. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 2003; 63(22): 7942-9.
88. Hodge JW, Higgins J, Schlom J. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. Vaccine 2009; 27(33): 4475-82.
89. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997; 15(6-7): 759-68.
90. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/ macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001; 61(1): 206-14.
91. Bos R, van Duikeren S, van Hall T, Lauwen MM, Parrington M, Berinstein NL, et al. Characterization of antigen-specific immune responses induced by Canarypox virus vaccines. J Immunol 2007; 179(9): 6115-22.
92. Schlom, J., Hodge, J.W., Panicali, D. Recombinant vector expressing multiple costimulatory molecules and uses thereof. US7771715 (2010).
93. Schlom, J., Panicali, D.L., Gritz, L.R., Mazzara, G.P. Recombinant poxvirus for immunization against tumor-associated antigens. US7410644 (2008).
94. Paoletti, E., Tartaglia, J., Cox, W.I. Poxvirus comprising DNA sequences encoding CEA and B7 antigen. US6780407 (2004).
95. Gabitzsch ES, Xu Y, Balint JP Jr, Hartman ZC, Lyerly HK, Jones FR. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunol Immunother 2010; 59(7): 1131-5.
96. Balint, J.P., Jones, F.R., Gayle III, R.B. Methods and compositions for producing an adenovirus vector for use with multiple vaccinations. US20100183673 (2010).
97. Kovesdi, I., Hedley, S.J. Capsid-incorporated antigen for novel adenovirus vaccine. US20110059135 (2011).
98. Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C, et al. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant. Hum Gene Ther 2004; 15(9): 856-64.
99. Ansardi DC, Moldoveanu Z, Porter DC, Walker DE, Conry RM, LoBuglio AF, et al. Characterization of poliovirus replicons encoding carcinoembryonic antigen. Cancer Res 1994; 54(24): 6359-64.
100. Cusi MG, Del Vecchio MT, Terrosi C, Savellini GG, Di Genova G, La Placa M, et al. Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine. J Immunol 2005; 174(11): 7210-6.
101. Huang Y, Fayad R, Smock A, Ullrich AM, Qiao L. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine. Cancer Res 2005; 65(15): 6990-9.
102. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63(10): 2462-9.
103. Facciabene A, Aurisicchio L, La Monica N. Baculovirus vectors elicit antigen-specific immune responses in mice. J Virol 2004; 78(16): 8663-72.
104. Kim, Y.-B., Lee, H.J., Park, N., Oh, Y.-K. Baculovirus-based vaccines. US20100285056 (2010).
105. Sandrine, C. Stabilizing formulations for recombinant viruses. US20090169581 (2009).
106. Paterson, Y., Peters, C., Gunn, G. Compositions and methods for enhancing the immunogenicity of antigens. US7700344 (2010).
107. Dubensky Jr., T.W., Brockstedt, D.G., Bahjat, K.S., Hearst, J.E., Cook, D.N., Luckett Jr., W.S. Modified free-living microbes, vaccine compositions and methods of use thereof. US7927606 (2011).
108. Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 2008; 14(13): 4316-25.
109. Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, Mostböck S, et al. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 2008; 26(4): 509-21.
110. Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immunother 2010; 59(3): 397-408.
111. Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccinemediated antitumor responses. Cancer Immunol Immunother 2011; 60(9): 1227-42.
112. Franzusoff, A., Bellgrau, D. Yeast-based vaccines as immunotherapy. US8153136 (2012).
113. Hodge, J., Schlom, J., Franzusoff, A. Combination immunotherapy compositions against cancer and methods. US20120107347 (2012).
114. Kost TA, Condreay JP. Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol 2002; 20(4): 173-80.
115. Salgaller ML, Bei R, Schlom J, Poole DJ, Robbins PF. Baculovirus recombinants expressing the human carcinoembryonic antigen gene. Cancer Res 1993; 53(9): 2154-61.
116. Bei R, Kantor J, Kashmiri SV, Schlom J. Serological and biochemical characterization of recombinant baculovirus carcinoembryonic antigen. Mol Immunol 1994; 31(10): 771-80.
117. Bei R, Guptill V, Masuelli L, Kashmiri SV, Muraro R, Frati L, et al. The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice. J Immunother 1998; 21(3): 159-69.
118. Woo SJ, Kim CH, Park MY, Kim HS, Sohn HJ, Park JS, et al. Coadministration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci 2008; 99 (5): 1034-9.
119. Waelti, E.R. Novel strategies for protein vaccines. US20060275777 (2006).
120. Türeci, Ö., Sahin, U., Kreiter, S. Recombinant vaccines and use thereof. US8178653 (2012).
121. Huarte E, Sarobe P, Lu J, Casares N, Lasarte JJ, Dotor J, et al. Enhancing immunogenicity of a CTL epitope from carcinoembry onic antigen by selective amino acid replacements. Clin Cancer Res 2002; 8(7): 2336-44.
122. Kobayashi H, Omiya R, Ruiz M, Huarte E, Sarobe P, Lasarte JJ, et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002; 8(10): 3219-25.
123. Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997; 3(12): 2439-49.
124. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997; 57(20): 4570-7.
125. Salazar E, Zaremba S, Arlen PM, Tsang KY, Schlom J. Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int J Cancer 2000; 85(6): 829-38.
126. +T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens. Cytokine 2003; 24(4): 128-42.
127. Dai S, Wan T, Wang B, Zhou X, Xiu F, Chen T, et al. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res 2005; 11(20): 7554-63.
128. Fikes, J.D., Sette, A., Sidney, J., Southwood, S., Celis, E., Keogh, E.A., Chestnut, R. Hla class I a2 tumor associated antigen peptides and vaccine compositions. US20030224036 (2003).
129. Schlom, J., Hodge, J., Zaremba, S., Salazar, M.E. Carcinoembryonic antigen (CEA) peptides. US20070048860 (2007).
130. Schlom, J., Barzaga, E., Zaremba, S. Agonist and antagonist peptides of carcinoembryonic antigen (CEA). US20100209386 (2010).
131. Hallermalm K, Johansson S, Bråve A, Ek M, Engström G, Boberg A, et al. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer. Scand J Immunol 2007; 66(1): 43-51.
132. Bråve A, Hallengärd D, Gudmundsdotter L, Stout R, Walters R, Wahren B, et al. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen. Vaccine 2009; 27(28): 3692-6.
133. Myers AL, Krewet JA, Shah MR. Tumor immunity and prolonged survival following combined adenovirus-HSP72 and CEA-plasmid vaccination. Vaccine 2005; 23(27): 3565-71.
134. Facciabene A, Aurisicchio L, Elia L, Palombo F, Mennuni C, Ciliberto G, et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther 2006; 17(1): 81-92.
135. Facciabene A, Aurisicchio L, Elia L, Palombo F, Mennuni C, Ciliberto G, et al. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigenspecific immune responses and antitumor effects. Vaccine 2007; 26(1): 47-58.
136. Aurisicchio L, Mennuni C, Giannetti P, Calvaruso F, Nuzzo M, Cipriani B, et al. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 2007; 120(11): 2290-300.
137. Mori F, Giannetti P, Peruzzi D, Lazzaro D, Giampaoli S, Kaufman HL, et al. A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Hum Gene Ther 2009; 20(2):125-36.
138. Peruzzi D, Dharmapuri S, Cirillo A, Bruni BE, Nicosia A, Cortese R, et al. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 2009; 27(9): 1293-300.
139. Aurisicchio, L., Palombo, F., Monaci, P., La Monica, N., Ciliberto, G., Lahm, A. Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof. US20060228335 (2006).
140. Aurisicchio, L., La Monica, N., Giannetti, P., Ciliberto, G. Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof. US20060286114 (2006).
141. La Monica, N., Lahm, A., Mennuni, C., Savino, R. Synthetic gene encoding human carcinoembryonic antigen and uses thereof. US20070104685 (2007).
142. La Monica, N., Facciabene, A., Aurisicchio, L., Ciliberto, G. Carcinoembryonic antigen fusion protein and uses thereof. EP1716173 (2012).
143. Bei R, Kantor J, Kashmiri SV, Abrams S, Schlom J. Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. J Immunother Emphasis Tumor Immunol 1994; 16(4): 275-82.
144. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87(13): 982-90.
145. Samanci A, Yi Q, Fagerberg J, Strigård K, Smith G, Rudén U, et al. Pharmacological administration of granulocyte/macrophagecolony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 1998; 47(3): 131-42.
146. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999; 17(9): 2889-95.
147. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18(23): 3964-73.
148. Conry RM, Allen KO, Lee S, Moore SE, Shaw DR, LoBuglio AF. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin Cancer Res 2000; 6(1): 34-41.
149. von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, et al. The influence of granulocyte macrophage colonystimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7(5): 1181-91.
150. Kerr D. Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 2003; 3(8): 615-22.
151. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005; 365(9454): 153-65.
152. Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004; 10(8): 2645-51.
153. Mosolits S, Harmenberg U, Rudén U, Ohman L, Nilsson B, Wahren B, et al. Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol Immunother 1999; 47(6): 315-20.
154. Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 2000; 60(17): 4850-4.
155. Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002; 8(9): 2782-7.
156. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105(7): 2862-8.
157. Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci 2009; 14: 1761-70.
158. Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine 2011; 29(39): 6817-22.
159. +immune responses and induce clinical benefit in vaccinated patients. Mol Ther 2011; 19(5): 990-9.
160. Foon KA, Chakraborty M, John WJ, Sherratt A, Köhler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96(1): 334-42.
161. Foon KA, John WJ, Chakraborty M, Sherratt A, Garrison J, Flett M, et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997; 3(8): 1267-76.
162. Chong G, Bhatnagar A, Cunningham D, Cosgriff TM, Harper PG, Steward W, et al. Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 2006; 17(3): 437-42.
163. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5(6): 1331-8.
164. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98(15): 8809-14.
165. Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 1999; 80(1): 92-7.
166. Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 2002; 51(2): 99-106.
167. Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21(3): 341-9.
168. Matsuda K, Tsunoda T, Tanaka H, Umano Y, Tanimura H, Nukaya I, et al. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004; 53(7): 609-16.
169. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 2004; 24(4): 909-17.
170. Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 2006; 55(3): 268-76.
171. Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, et al. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother 2011; 60(11): 1565-75.
172. Perroud MW Jr, Honma HN, Barbeiro AS, Gilli SC, Almeida MT, Vassallo J, et al. Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. J Exp Clin Cancer Res 2011; 30: 65.
173. Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 2011; 60(10): 1497-502.
174. Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 2010; 30(12): 5091-7.
175. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004; 22(14): 2808-15.
176. Wroblewski JM, Bixby DL, Borowski C, Yannelli JR. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumorassociated antigens. Lung Cancer 2001; 33(2-3): 181-94.
177. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007; 57(3): 365-72.
178. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother 2007; 56(12): 2003-16.
179. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005; 115(12): 3623-33.
180. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 2006; 177(1): 84-91.
181. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007; 110(9): 3192-201.
182. +human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007; 120(12): 2723-33.
183. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112(3): 610-8.
184. Hamilton JM, Chen AP, Nguyen B. Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. Proc Am Soc Clin Oncol 1994; 13: 961.
185. Conry RM, Saleh MN, Schlom J, Lo Buglio AF. Breaking tolerance to carcinoembryonic antigen with a recombinant vaccinia virus vaccine in man. Proc Am Assoc Cancer Res 1995; 36: 2930.
186. Conry RM, Khazaeli MB, Saleh MN, Allen KO, Barlow DL, Moore SE, et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999; 5(9): 2330-7.
187. Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, et al. Phase I study in cancer patients of a replicationdefective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999; 17(1): 332-7.
188. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000; 6(1): 24-33.
189. von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000; 6(6): 2219-28.
190. Horig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000; 49(9): 504-14.
191. Kalus RM, Kantor JA, Gritz L, Gomez Yafal A, Mazzara GP, Schlom J, et al. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 1999; 17(7-8): 893-903.
192. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J, et al. A triad of costimulatory molecules synergize to amplify Tcell activation. Cancer Res 1999; 59(22): 5800-7.
193. Freund YR, Mirsalis JC, Fairchild DG, Brune J, Hokama LA, Schindler-Horvat J, et al. Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. Int J Cancer 2000; 85(4): 508-17.
194. Marshall J. Carcinoembryonic antigen-based vaccines. Semin Oncol 2003; 30(3 Suppl 8): 30-6.
195. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005; 23(4): 720-31.
196. Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, et al. Phase I study of aMUC1vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005; 54(3): 254-64.
197. Wierecky J, Mueller M, Brossart P. Dendritic cell based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 2006; 55(1): 63-7.
198. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 2004; 27(3): 240-53.
199. Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 2004; 10(6): 2139-49.
200. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008; 14(10): 3060-9.
201. Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 2008; 14(15): 4843-9.
202. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70(3): 875-82.
203. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated Tcell killing. Cancer Res 2004; 64(12): 4328-37.
204. Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, et al. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther 2011; 11(11): 1409-18.
205. Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, et al. A pilot study of MUC-1/CEA/TRICOM poxviralbased vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011; 17(22): 7164-73.
206. Jiang XP, Yang DC, Elliott RL, Head JF. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients. Cancer Biother Radiopharm 2000; 15(5): 495-505.
207. Ullenhag GJ, Frödin JE, Jeddi-Tehrani M, Strigård K, Eriksson E, Samanci A, et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/ macrophage colony-stimulating factor. Clin Cancer Res 2004; 10(10): 3273-81.
208. Marshall JL, Tsang K, Arlen P, Ley L, Slack R, Toomey MA, et al. Phase I trial to determine the toxicity and immunologic efficacy of the addition of GM-CSF and IL-2 to the combination of vaccinia-CEA and ALVAC-CEA administered as a prime and boost in patients with advanced CEA-bering cancers. Proc Am Soc Clin Onc 2001; 20(abstr 1087): 272A.
209. Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med 2007; 5: 60.
210. Schlom J. Therapeutic cancer vaccines: Current status and moving forward. J Natl Cancer Inst 2012; 104(8): 599-613.
211. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-23.
212. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: The potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 2011; 236(5): 567-79.